- Micro-invasive glaucoma implants (MIGS), designed to lower intraocular pressure with minimal trauma, are becoming increasingly vital in the treatment of mild-to-moderate glaucoma due to their safety profile, shorter recovery times, and compatibility with cataract surgeries
- The rising demand for MIGS is primarily driven by the growing prevalence of glaucoma globally, increasing geriatric population, advancements in ophthalmic surgical technologies, and the preference for minimally invasive procedures by both patients and ophthalmologists
- North America dominates the micro-invasive glaucoma implants market, with the largest revenue share of 36.7% in 2024, fueled by high awareness levels, early adoption of innovative ophthalmic procedures, favorable reimbursement policies, and the presence of key industry players
- Asia-Pacific is expected to be the fastest growing region in the micro-invasive glaucoma implants market during the forecast period, with a CAGR of 9.6%, driven by increasing healthcare expenditures, rising glaucoma incidence, and expanding access to advanced eye care in countries such as India and China
- The trabecular micro-bypass stents segment dominates the MIGS market, with a market share of 65% in 2024. This dominance is attributed to their proven efficacy, ease of implantation, and strong clinical backing, making them a preferred choice among ophthalmic surgeons worldwide
